#### Inferring the role of the microbiome on survival in patients treated 1 with immune checkpoint inhibitors: causal modeling, timing, and classes of 2 concomitant medications 3 4

5	Daniel Spakowicz <sup>1,2§*</sup> , Rebecca Hoyd <sup>1§</sup> , Mitchell Muniak <sup>1</sup> , Marium Husain <sup>1</sup> , James S.		
6	Bassett <sup>1</sup> , Lei Wang <sup>2</sup> , Gabriel Tinoco <sup>1</sup> , Sandip H. Patel <sup>1</sup> , Jarred Burkart <sup>1</sup> , Abdul Miah <sup>1</sup> , Mingjia		
7	Li <sup>3</sup> , Andrew Johns <sup>1</sup> , Madison Grogan <sup>1</sup> , David P. Carbone <sup>1</sup> , Claire F. Verschraegen <sup>1</sup> , Kari L.		
8	Kendra <sup>1</sup> , Gregory A. Otterson <sup>1</sup> , Lang Li <sup>2</sup> , Carolyn J. Presley <sup>1</sup> , and Dwight H. Owen <sup>1</sup>		
9	<sup>1</sup> Division of Medical Oncology, Department of Internal Medicine, Ohio State University,		
10	Columbus, OH, USA		
11	<sup>2</sup> Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA		
12	<sup>3</sup> Division of Hospital Medicine, Department of Internal Medicine, The Ohio State		
13	University College of Medicine		
14	<sup>§</sup> These authors contributed equally		
15	*To whom correspondence should be addressed: Daniel.Spakowicz@osumc.edu		
16			

## 17 ABSTRACT

18 The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors 19 (ICIs) in a small number of cancers. Here, we sought to more broadly survey cancers to identify 20 those in which the microbiome will play a role using retrospective analyes. We created a causal 21 model for the relationship between medications, the microbiome and ICI response and used it to 22 guide the abstraction of electronic health records of 690 patients who received ICI therapy for 23 advanced cancer. Medications associated with changes to the microbiome including antibiotics, 24 corticosteroids, proton pump inhibitors, histamine receptor blockers, non-steroid anti-25 inflammatories and statins were abstracted. We tested the effect of medication timing on overall 26 survival (OS) and evaluated the robustness of medication effects in each cancer. Finally, we 27 compared the size of the effect observed for antibiotics classes to taxa correlated with ICI 28 response and a literature review of culture-based antibiotic susceptibilities. Of the medications 29 assessed, only antibiotics and corticosteroids significantly associated with lower OS. The 30 hazard ratios (HRs) for antibiotics and corticosteroids were highest near the start of ICI 31 treatment but remained significant when given prior to ICI. Antibiotics and corticosteroids 32 remained significantly associated with OS even when controlling for multiple factors such as 33 Eastern Cooperative Oncology Group performance status and stage. When grouping antibiotics 34 by class,  $\beta$ -lactams showed the strongest association with OS across all tested cancers. The 35 timing and strength of these effects after controlling for confounding factors are consistent with 36 role for the microbiome in response to ICIs.

37

### 38 KEYWORDS (6)

39 Microbiome, immune checkpoint inhibitors, antibiotics, corticosteroids, cancer,40 immunotherapy

### 41 BACKGROUND

Treatment with Immune Checkpoint Inhibitors (ICIs) has improved patient outcomes across a wide variety of cancers. Not all patients respond to these drugs and there is a need to identify biomarkers of outcomes. Three recent studies have shown that microbes are associated with response and overall survival (OS) in renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and melanoma (1–3). The microbiome may be a key player in response to ICI therapy and a potential biomarker of treatment response.

The microbiome is known to interact with the immune system, but how it affects response to ICIs is not understood. The effectiveness of ICI treatment relies on active T-cell infiltration of a tumor; microbes have been associated with increased Tumor Infiltrating Lymphocytes in an IL12-depended manner (4). However, other immune cells dampen response to ICIs such as myeloid-derived suppressor cells and FOXP3 & CD4+CD25+ T-regulatory cells. Another, systemic form of immune repression is characterized by the production of prostaglandins (5–7).

55 Several medications commonly used during routine oncologic care and ICI treatment 56 can influence inflammation pathways and/or the microbiome. Corticosteroids (CS) affect both of 57 the aforementioned T-cell subtypes and the prostaglandin-related inflammatory pathways (8). 58 Additionally, antibiotics (ABx) have a direct effect on the microbiome by killing or halting the 59 growth of bacteria. Proton pump inhibitors (PPIs), histamine 2 blockers (H2Bs), non-steroid anti-60 inflammatory drugs (NSAIDs), and CS have also been associated with changes in the 61 microbiome but, in contrast to antibiotics, this mechanism is indirect (9). PPIs, by inhibiting 62 gastric acid secretion, alter the pH of the gut and change the number and types of bacteria that 63 pass through the stomach (10). Notably, if the taxa enriched by the PPI-induced pH change are 64 also important for response to ICIs, then PPI treatment during ICI may influence clinical

outcomes. The effect of other medications on clinical response may be challenging to interpretgiven that the effects may influence both the microbiome and ICI response.

67 In order to disentangle these complex interactions, we created a model of the 68 relationship between patient characteristics, medications that affect the microbiome, 69 inflammation, and survival. Second, we performed a retrospective analysis of patients who 70 received ICI therapy for advanced cancer between 2011 and 2017 including medications with 71 known effects on either the microbiome or its pathway toward affecting ICI response. Third, we 72 estimated the association for each medication with OS. Fourth, we analyzed the effects of 73 medications longitudinally, in order to decouple confounding variables at different time points. 74 Fifth, we controlled for variables that broadly describe differences in baseline statuses (e.g. 75 Eastern Cooperative Oncology Group performance status (PS)) of individuals who received 76 concomitant medications and those who did not. Sixth, we compared the associations across 77 several cancers, for which the medications are prescribed in subtly different ways that can be 78 leveraged to gain further insight into the causal effects. Finally, we related these results to the 79 microbes shown to be enriched or depleted in individuals who respond to ICIs. The combination 80 of these strategies gives layers of support to defining the role of the microbiome in the context 81 ICI treatment of cancer.

82

#### 83 METHODS

#### 84 Causal Model

We performed a literature review of the relationship between the microbiome and response to ICIs and medications that affect the microbiome (**Figure 1**, references in **Figure S1**). From these references, a causal model was then constructed such that the nodes correspond to observable endogenous variables (*V<sub>i</sub>*), as a subset of a set of *U* exogenous and unobserved variables that affect the relationship between the microbiome and OS in patients

90 treated with ICIs. Directed edges denote a relationship between variables when the following 91 conditions are met: (1) there is a reported relationship between variables in which both variables 92 were either observed or defined by intervention, and (2) the relationship cannot be explained 93 through using an existing path. For example, Gopalakrishnan et al reported a correlation 94 between the microbiome and ICI response (1). This relationship exists in the graph as mediated 95 by the nodes Microbiome  $\rightarrow$  T-cell Mediated Inflammation  $\rightarrow$  ICI Response, therefore no edge 96 is drawn directly from Microbiome  $\rightarrow$  ICI Response. The resulting directed acyclic graph was 97 constructed using the igraph and dagitty packages in R (11,12).

## 98 Retrospective data collection

99 We identified patients with advanced cancer treated between 2011 and 2017 at the Ohio

100 State University Comprehensive Cancer Center/Arthur G. James Cancer Hospital (OSUCCC-

101 James) who received at least one dose of ICIs as part of an IRB approved retrospective study

102 (OSU-2016C0070, OSU-2017C0063). Patient data were collected and housed in REDCap (13).

103 Medication timing, dose and names were collected from the electronic medical record

104 information warehouse and validated by manual chart review.

## 105 Medication history curation

ABx and CS data were retrieved from the information warehouse within 180 days of ICI start. All medications matching a comprehensive list of steroid generic and brand names were collected with dates and routes of administration. Medications were filtered to those confirmed to be administered and the results checked against a manually-curated subset of the records.

#### 110 Survival Analysis

Overall survival (OS) was reported in days from the initiation of ICI to the date of death
or last follow-up. All univariate and multivariate analyses were conducted using the survminer
package in R (14,15). Univariate analyses used Kaplan-Meier survival curves with log-rank

#### 114 tests. Multivariate analyses used Cox-Proportional Hazards models, defining the hazard

115 function for each patient *k* as:

116 
$$h_{k}(t) = h_{0}(t)e^{\{\sum_{t=1}^{n}\beta_{1}A + \beta_{2}S + \beta_{3}B + \beta_{4}E + \beta_{5}G\}}$$

117 Where h(t) is the hazard function at time t = 1 to *n*, *A* is a binary indicator of antibiotic 118 use (+/- 28 days from start of ICIs), *S* is a binary indicator of corticosteroid use (+/- 28 days from 119 start of ICIs), *B* is BMI, *E* is the Eastern Cooperative Oncology Group performance status (PS) 120 score (1-5), and *G* is age. We constructed the models using the survival package and evaluated 121 model fits using a likelihood ratio tests in R (16–18).

#### 122 Timing analysis

123 A 30-day sliding window was used to evaluate the effect of medication timing on the 124 association with OS. Patients prescribed medications within the window were compared to a 125 cohort of individuals who were not prescribed those medications within 180 days before or after 126 the start of ICI treatment. Kaplan-Meier survival curves were used to estimate a hazard ratio 127 (HR) of association with each treatment window, incremented by single-days, e.g. prescribed 128 180-150 days before ICI start vs no prescribed medications, and then prescribed 179-149 days 129 before ICI start vs no prescribed medications. HRs and confidence intervals were calculated in 130 the survival package and plotted with ggplot2 in R (17–19).

131 Antibiotics and Corticosteroids classes

ABx and CS were collapsed into categories by DrugBank v5.0 accession numbers (20). HRs were estimated for medication class and cancer combinations if the total sample set included at least 20 individuals. Cox Proportional Hazards models for the effects of ABx and CS class were used to allow for simultaneous estimation of the effects of more than one class, when applicable. Plots showing prescriptions of more than one class were created with the UpSetR package in R (21).

### 138 Regularized Cox Regression

- 139 Regularized Cox survival models for each cancer were implemented in the glmnet
- package in R. We optimized the regularization parameter by coordinate descent via 10-fold
- 141 cross-validation and then tested the robustness of the parameter selection and resulting
- 142 covariates with 1000 bootstrap replicates of different random samples of the dataset (22,23).

#### 143 **Reproducibility**

- 144 Scripts to reproduce all figures and analyses can be found at
- 145 https://github.com/spakowiczlab/co-med-io.
- 146

#### 147 **RESULTS**

#### 148 Causal Model

149 The relationships between clinical variables, medications, the microbiome, ICI response 150 and OS are strongly interconnected. Our literature review to predict their causal relationships 151 (Figure 1) led to several hypotheses observable within retrospective data. First, medications 152 that directly affect the microbiome will alter OS via effects on T-cell mediated inflammation (i.e. 153 ABx  $\rightarrow$  Microbiome  $\rightarrow$  T-cell mediated inflammation  $\rightarrow$  ICI Response  $\rightarrow$  OS). Second, CS and 154 ABx may have additive effects on ICIs through a collider effect on T-cell mediated inflammation 155 (i.e. ABx  $\rightarrow$  Microbiome  $\rightarrow$  T-cell mediated inflammation  $\leftarrow$  CS). Finally, the clinical variables of 156 stage, BMI, age, and medications such as CS, confound the relationship between the 157 microbiome and ICI response, mediated by Prostaglandin-based inflammation (which itself is a 158 collider), and therefore must be controlled for in order to infer the role of the microbiome on OS 159 (Figure 1).

## 160 Patient Characteristics

161 Retrospective analysis of electronic medical records from 2011 to 2017 at the OSUCCC-162 James identified 690 patients treated with ICIs (**Table 1**). Most (76.6%) had a PS of 0 or 1. The

most common diagnoses were melanoma (28.5%) and non-small cell lung cancer (NSCLC)
(23.4%). Cancers represented by fewer than 20 patients were categorized as "Other" (23.4%).
The majority of patients (90%) had metastatic disease. ICI treatments included nivolumab in
52.8% of patients, ipilimumab in 18.0% and pembrolizumab in 15.1%.

167 Microbiome and inflammation-related concomitant medication use

168 Among the medications included in the causal model, ABx, CS, PPIs, H2Bs, statins and 169 NSAIDs were identified in this cohort. ABx were prescribed in 35% of patients within 28 days of 170 the start of ICIs (Table 1). The most commonly prescribed ABx were  $\beta$ -lactams (**Figure S1**). CS 171 were prescribed in 40% patients within 28 days of the start of ICIs. The most commonly 172 prescribed CS were dexamethasone and prednisone (Figure S2). PPIs were prescribed in 37% 173 of patients. Some patients received a single medication and no others during the study period. 174 however, more frequently patients received several medications, e.g. CS with PPI and ABx, 175 consistent with prophylaxis for developing an ulcer or pneumonia (Figure S3). The analysis 176 strategy first tested for an association of a medication with OS without controlling for 177 confounding effects of other medications and then further explored those medications with

178 strong associations.

179 Across all cancer types, patients who were prescribed ABx within 28 days of the start of 180 ICIs showed decreased OS (Figure 2A). This was also true of patients prescribed CS (Figure 181 2B), but not of patients prescribed other medications (Figure 2C). ABx showed a strong 182 negative correlation with OS in RCC, NSCLC, melanoma, and bladder cancer. CS showed a 183 strong negative correlation with OS in NSCLC, melanoma and other cancers. While other 184 medications were not significantly associated with OS across all cancers, several showed 185 significant associations with specific cancers. For example, H2Bs and NSAIDs associated with 186 decreased OS in sarcoma and NSCLC, respectively. On the other hand, PPIs and Statins

positively associated with OS in sarcoma. However, we observed the strongest associations for
ABx and CS, and therefore followed these medications in further analyses.

189 Timing of medication use

Next we focused on the timing of ABx and CS prescriptions and their associations with OS in each cancer, using a 30-day sliding window (see Methods). ABx showed a greater HR than CS over nearly the entire period, and both were negatively associated with OS (**Figure 3A**). ABx treatment showed the highest HR more than 100 days before the start of ICIs with a second, lesser peak around day 0. CS showed a single, strong peak at day 0. We therefore focused the timing analyses around ICI day 0 to capture the largest HR for both ABx and CS and examined the effects across cancers and drug subclasses.

## 197 Antibiotics and Corticosteroids classes

198 The effect of ABx on treatment response in different cancer types was not consistently 199 associated with ABx class (Figure 3B). For example,  $\beta$ -lactams showed the highest HR in 200 melanoma, but vancomvcin (oral) had the highest HR in head and neck squamous cell 201 carcinoma (HNSC). In addition, the overall effect of ABx was sometimes associated with a 202 single ABx subclass and sometimes distributed over many. Additionally, NSCLC strongly 203 associated with fluoroquinolone ABx, and this effect was stronger than the effect observed for 204 all ABx combined. By contrast, the combined effect of all ABx in melanoma was much stronger 205 than any individual ABx class. In fact, tetracycline was positively associated with OS in 206 melanoma patients, despite the overall effect of ABx being negatively associated. On the other 207 hand, the effects of CS classes on different cancers was more consistent (Figure 3C), though 208 these comparisons were often limited by the sample size. Particularly with small sample sizes, 209 confounding effects of patients receiving multiple drugs, e.g. ABx and CS, may dominate 210 associations with OS. We therefore used combined models of ABx and CS to examine the 211 effects of each.

## 212 Combined modeling of ABx and CS, controlling for covariates

213 Models containing both ABx and CS showed that both are significantly associated with 214 OS. A Kaplan-Meier curve stratifying patients by ABx, CS, or both, showed nearly identical 215 intermediate effects of either ABx or CS, and an additive combined effect (Figure 4A). We next 216 sought to control for confounding covariates using a Cox Proportional Hazards model. Including 217 PS, BMI, sex, stage, and age in the model confirmed that ABx and CS remained highly 218 significant, as were PS, BMI and age (Figure 4B). This suggests that ABx and CS are affecting 219 OS in the context of ICI therapy by a mechanism other than that which is captured by PS, BMI 220 or age, and is consistent with the microbiome parent to T-cell inflammation and child of ABx 221 (Figure 1).

222 In order to estimate the effects of ABx and CS within each cancer, we applied a method 223 that (1) allowed different covariates to be included in each cancer, commensurate with the 224 different clinical features of each cancer, and (2) removed uninformative variables, increasing 225 the power for those cancers with smaller numbers of patients in this dataset. In addition, we 226 repeated the analysis with different random samplings of the data in order to estimate the 227 robustness of the variable selection. We found ABx to consistently and significantly associate 228 with OS in bladder cancer, melanoma and RCC, but not in HNSC, NSCLC, or sarcoma. The HR 229 was above 1 in each of the cancers where ABx was a consistently-selected covariate. 230 Melanoma was notable in that all variables were consistently selected, with ABx showing the 231 highest HRs.

## 232 The relationship between ABx, OS, and the microbiome

The bacterial taxa that showed the strongest enrichment in responders or nonresponders to ICIs were selected from the literature and combined into a phylogenetic tree (**Figure 5**) (1–3). The taxa spanned several phyla and few ranks were consistently enriched in either responders or non-responders. For example, Firmicutes was found to be enriched in

responders (1), but within the phylum are several taxa found to be enriched in non-responders 237 238 (2,3). An exception to this was Bacteroidetes, which was found to be enriched in non-239 responders and each of the four species in the phylum were also enriched in non-responders 240 (1,3). We performed a literature review of ABx susceptibilities for each of these taxa to estimate 241 whether the size of the HR of the ABx would relate to the taxa for which it is active. For 242 example, an ABx that target only bacteria enriched in non-responders may be beneficial 243 because it may shift the community toward those taxa enriched in responders. On the other 244 hand, if the overall diversity of the microbiome is important, broad-spectrum ABx may have 245 higher HRs than narrow-spectrum. 246 The ABx class with the largest HR across all cancers was the  $\beta$ -lactams. Within this 247 group category are the cephalosporins, which have a relatively narrow spectrum of activity and 248 a unique pattern relative to other ABx classes. The cephalosporins are ineffective against the 249 Bacteroidetes, found to be enriched in non-responders, but so were ABx such as vancomycin 250 and sulfamethoxazole-trimethoprim (SXT). However, unlike vancomycin and SXT, 251 cephalosporins effectively target A. muciniphila, which was shown to causally modify response 252 to ICIs. Cephalosporins are also ineffective against several Firmicutes, similar to clindamycin, macrolides and metronidazole (Figure 5). 253

254

## 255 **DISCUSSION**

The effects of medications or other variables are difficult to parse in a dynamic setting such as during treatment for cancer. We used a variety of methods to show that ABx and CS are significantly associated with decreased OS in several cancer types and that these results are consistent with mediation via the gut microbiome.

260 The association of CS with ICI response and OS remains controversial. Our observed 261 association is consistent with other observations of decreased OS in NSCLC (8). However, 262 Riccuiti et al showed no effect of CS on OS in NSCLC when given on the same day as ICI start. 263 when the CS was prescribed for reasons other than "cancer-related palliative indications" (24). 264 Our records lack some variables needed to replicate those results, however our results are 265 consistent with aspects those findings. For example, dexamethasone treatment showed a 266 strong negative association with OS across several cancer types, consistent with its use for 267 brain metastases and anorexia, which are all indicators of poor clinical outcome. On the other 268 hand, several of our analyses demonstrated associations between CS and OS that may not be 269 due to selecting a sub-cohort with a poor prognosis. Our first causal strategy, the time analysis, 270 showed similar results when restricting CS medications to a single day, but a larger effect when 271 a wider time window was used (**Table 2**). Our second causal strategy, controlling for covariates, 272 cannot be directly compared because our dataset did not include central nervous system 273 metastases. However, when we control for metastatic stage and PS, the CS association 274 remains. Our third causal strategy, comparisons between cancers, shows that the CS 275 association with OS is observed in cancers for which brain metastases are not common, such 276 as RCC, and for specific CS not typically used for brain metastases, such as 277 methylprednisolone in HNSC. This suggests that understanding the association between CS 278 and the response to ICIs may require more granular assessment of CS types (i.e. rather than 279 collapsing to 10 mg prednisone equivalent) and cancers.

We applied the same logical framework to ABx treatment to demonstrate an effect on OS. Unlike CS, the majority of studies have found an association between ABx use and ICI response, independent of the time window (**Table 2**). First, our longitudinal analysis showed a global maximum HR well before the start of ICIs, consistent with the ABx effects persisting for long periods. Given this result, it is unlikely that acute illnesses drive the association between

285 ABx and OS. Second, when controlling for illness-related covariates that report on the overall 286 health status of the individual, e.g. PS, the effect of ABx remained significant. Third, the 287 associations of ABx and OS were observed across cancer types (e.g. patients with bladder 288 cancer versus melanoma). A larger fraction of bladder cancer patients were treated with ABx 289 than any other cancer (56%), consistent with their use for urinary tract or as prophylaxis for 290 invasive urologic procedures. On the other hand, melanoma patients treated with ABx were the 291 smallest fraction of any cancer (25%), consistent with this population being less likely to 292 undergo procedures in which prophylactic ABx are used. It is reasonable to suspect that 293 melanoma patients treated with ABx are therefore more compromised than those not treated 294 with ABx. However, an effect of ABx remains, even for bladder cancer. Although it remains 295 probable that the cohorts who receive ABx are different from those who did not in ways that 296 have not been controlled for in analyses, these three analyses add confidence to the 297 association of ABx with OS in the context of ICIs.

298 We next related the strength of the association of ABx classes with OS and the microbes 299 that those ABx classes affect. The  $\beta$ -lactam ABx were shown to have the strongest association 300 with OS across cancer types. The literature review of antibiotic susceptibilities showed that this 301 diverse class is effective against the Gram-positive phylum Firmicutes. The literature review of 302 the bacterial taxa associated with response to ICIs, showed that the Firmicutes are enriched in 303 responders to ICIs. Moreover, β-lactams are not consistently effective against members of the 304 phylum Bacteroidetes, which was found to be enriched in non-responders. This suggests that 305 the  $\beta$ -lactams may show the strongest signal across all cancers in our dataset because they 306 disrupt the microbiome in such a way that they reduce response to ICIs by depleting the 307 Firmicutes more so than the Bacteroidetes.

The association between ABx prescriptions and OS that we observe is consistent with direct measurements of the microbiome and response to ICIs (1–3). However, there is no

310 consensus for which taxa are enriched in the responders to ICIs (**Figure 5**). For example, there 311 is causal evidence for Akkermansia muciniphila increasing response to ICIs, however, it was not 312 among the most enriched in the other datasets (1–3). Nonetheless, agreement can be observed 313 at broader taxonomic characterizations. Non-responders are enriched for taxa in the phylum 314 Bacteroidetes and this is consistent with the strength of association we see for different classes 315 of ABx (1,3). Narrow spectrum  $\beta$ -lactams (e.g. cephalosporins), which show the strongest 316 association with OS, are effective against Firmicutes (enriched in responders) but less so 317 against Bacteroidetes (enriched in non-responders).

The results presented here contrast with several assumptions gathered from the literature and described by the causal model (**Figure 1**). First, we found that ABx and CS are the only medications significantly associated with OS, despite the inclusion of several medications associated with changes to the microbiome (**Figure 2**). This may be due to the types of changes incurred (e.g. PPIs may not significantly change the abundances of those taxa linked to ICI response) or the strength of the effect amid the noise in the data. However, the other two hypotheses were borne out by the analyses.

The CS and ABx medications showed an additive effect on OS, consistent with a collider interaction in the model (**Figure 4A**). Also, there was an effect of ABx after controlling for many covariates, consistent with its direct effect on the microbiome and the microbiome playing a role in ICIs (**Figure 4B**). This result was consistent with the relationship between the strength of the ABx signal and the bacterial taxa susceptible to that ABx (**Figure 5**).

330 Limitations

A key challenge in this and other retrospective analyses is inferring causal relationships
in non-randomized cohorts. For example, patients who receive medications such as antibiotics
may be quite different from those who do not. However, it is difficult to imagine an ethical trial

that could randomize treatment with ABx in this setting. Therefore, retrospective analyses may
be the best option until direct measurements of the microbiome are widely available. We used a
variety of methods to show that ABx and CS are significantly associated with decreased OS
across a variety of cancers and that these results are consistent with a role for the gut
microbiome.

339 Our study remains limited by being unable to account for important factors known to 340 affect OS in the context of ICI treatment. For example, the complete ABx history of patients --341 much longer than the windows reported here -- are very likely of consequence. Several groups 342 have studied the recovery of microbiome diversity following ABx exposure and results show 343 reasonable recovery 90 days later (25,26). However, multiple courses of ABx prevented such a 344 recovery; i.e. diversity returned to baseline after one treatment with ABx, but not after a second 345 ABx treatment within 60 days (27). It is therefore possible that individuals who show extreme 346 effects of ABx treatment are beyond the time scale of this study. Without baseline microbiome 347 diversity measures we are unable to capture such information. Similarly, estimating the effects 348 of ABx on communities from data on microbes in isolation is, at best, approximate. A better 349 understanding of how ABx affect complex communities is needed. Other limitations include our 350 small sample size relative to the heterogeneity in the data. Future directions should capture 351 variables such as other co-morbidities or the presence of brain metastases, tumor biomarkers 352 such as tumor mutational burden and PD-1/PDL-1 status, and outcome variables like ICI 353 response or the number of tumor-infiltrating lymphocytes.

354

### 355 CONCLUSIONS

ABx and CS, but not other medications known to affect the microbiome, are associated
 with reduced OS when administered near the start of ICI treatment. Our results show this finding

358 several cancer types, and for several subclasses of these drugs. These results are consistent

359 with a role of the microbiome in response to ICIs and identify clinical settings where the

360 microbiome is likely to play the largest role, namely NSCLC, melanoma, RCC, HNSC, and

- 361 bladder cancer. A clear understanding of which microbes are important for ICI responses and in
- 362 what cancers will require the collection of microbiome samples across a wide variety of clinical
- 363 settings. However, some information can be gathered by indirect means, which identifies the
- 364 settings where the microbiome is likely to have the greatest effects. Medications that affect the
- 365 microbiome given concomitantly with ICIs provide evidence for where microbes play a role.
- 366 Further work is needed to identify which microbes are important and identify solutions to
- 367 mitigate these effects and perhaps promote greater response to ICIs.

## 369 LIST OF ABBREVIATIONS

- 370 ICIs: Immune Checkpoint Inhibitors
- 371 OS: Overall Survival
- 372 ABx: Antibiotics
- 373 CS: Corticosteroids
- 374 PS: Eastern Cooperative Oncology Group Performance Status
- 375 BMI: Body Mass Index
- 376 NSCLC: Non-Small Cell Lung Cancer
- 377 RCC: Renal Cell Carcinoma
- 378 HNSC: Head and Neck Squamous Cell Carcinoma
- 379

## 380 **DECLARATIONS**

- 381 Ethic Approval and Consent to Participate
- 382 Data from this work were collected under an IRB-approved retrospective study (OSU-
- 383 2016C0070, OSU-2017C0063).
- 384 **Consent for Publication**
- 385 Not applicable.

## 386 Availability of Data and Materials

- 387 Scripts to reproduce all figures and analyses can be found at
- 388 <u>https://github.com/spakowiczlab/co-med-io</u>.
- 389 Competing Interests

390	DHO has a consulting or advisory role to L&M Policy Research and AstraZeneca. DHO
391	has research funding from Bristol-Myers Squibb, Palobiofarma, Merch Sharp & Dohme and
392	Genentech/Roche. DHO received travel, accommodations and/or expenses from AstraZeneca.
393	DPC is on the advisory board of Abbvie, AMGEN, Ariad, AZ, Biocept, BI, BMS, Celgene, EMD
394	Serono, Genentech, Gritstone, Helsinn, Inivata, Inovio, Janssen, Loxo Oncology, Merck, MSD,
395	Pfizer, Roche, Takeda, and Trinity. DPC received honoraria from AstraZeneca and Nexus
396	Oncology. DPC is a consultant for Abbvie, Agenus, Ariad, Celgene, Genentech, Incyte, Inivata,
397	Janssen, Kyowa Kirin, Loxo, MSD, Novartis, Pfizer and Takeda.
398	Funding
399	This project was supported by The Ohio State University Center for Clinical and

400 Translational Science grant support (National Center for Advancing Translational Sciences,

401 Grant 8UL1TR000090-05) and a P30 CCSG award (2 P30 CA016058-42). Daniel Spakowicz is

402 supported by a Pelotonia New Investigator Award and Carolyn Presley is a Paul Calabresi

403 Scholar supported by the OSU K12 Training Grant for Clinical Faculty Investigators (5K12

404 CA133250-09). No funding body was involved in the design of the study or the collection,

405 analysis, or interpretation of data, or in writing the manuscript.

## 406 Author's Contributions

407 MH, GT, SP, JTB, CFV, KLK, SH, JP, DQ, GAO, MG, CP and DHO collected the data.

408 RH, MM, JB, LW, LL, DPC, DHO and DS analyzed the data and generated the figures and

tables. DS, RH and DHO wrote the manuscript. All authors read and approved the final

410 manuscript.

## 411 Acknowledgements

412 This work was performed on the Ohio Supercomputer Center servers (Owens, Pitzer;

413 Project PA1490 awarded to Daniel Spakowicz). The authors would like to thank Stephanie

- 414 Fortier (Division of Medical Oncology, The Ohio State University; ORCID 0000-0002-2380-
- 415 2378) for critically reviewing and editing the manuscript.

416

## 417 **REFERENCES**

- Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut
   microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients.
   Science. 2018 Jan 5;359(6371):97–103.
- Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients.
   Science. 2018 Jan 5;359(6371):104–8.
- Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, et al. Gut microbiome
   influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science.
   2018;359(6371):91–97.
- 4. Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4
  Blockade. Science. 1996 Mar 22;271(5256):1734–6.
- 5. Chen P-L, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6(8):827–37.
- 433 6. Limagne E, Richard C, Thibaudin M, Fumet J-D, Truntzer C, Lagrange A, et al. Tim434 3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1
  435 blockade in lung cancer patients. Oncoimmunology. 2019;8(4):e1564505.
- 436 7. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of
  437 neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med.
  438 2019;25(3):454–61.
- Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of Baseline Steroids
  on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in
  Patients With Non–Small-Cell Lung Cancer. JCO. 2018 Oct;36(28):2872–8.
- 442 9. Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the
  443 gut microbiome. Clinical Microbiology and Infection. 2016 Feb 1;22(2):178.e1-178.e9.
- Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors
  affect the gut microbiome. Gut. 2016 May;65(5):740–8.
- 446 11. Csardi G, Nepusz T. The igraph software package for complex network research.
  447 InterJournal. 2006;Complex Systems:1695.


- Textor J, Zander B van der. dagitty: Graphical Analysis of Structural Causal Models
   [Internet]. 2016. Available from: https://CRAN.R-project.org/package=dagitty
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
  capture (REDCap)--a metadata-driven methodology and workflow process for providing
  translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377–81.
- 453 14. Kassambara A, Kosinski M. survminer: Drawing Survival Curves using "ggplot2" [Internet].
  454 2018. Available from: https://CRAN.R-project.org/package=survminer
- 455 15. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
  456 Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from:
  457 https://www.R-project.org/
- 458 16. Zeileis A, Hothorn T. Diagnostic checking in regression relationships. 2002 [cited 2017
   459 May 8]; Available from: http://idg.pl/mirrors/CRAN/web/packages/Imtest/vignettes/Imtest 460 intro.pdf
- 461 17. Therneau TM. A Package for Survival Analysis in S [Internet]. 2015. Available from:
   462 https://CRAN.R-project.org/package=survival
- 463 18. Terry M. Therneau, Patricia M. Grambsch. Modeling Survival Data: Extending the Cox
  464 Model. New York: Springer; 2000.
- 465 19. Wickham H. ggplot2: elegant graphics for data analysis [Internet]. Springer Science &
  466 Business Media; 2009 [cited 2015 Dec 14]. Available from:
  467 https://books.google.com/books?hl=en&Ir=&id=bes-
- 468 AAAAQBAJ&oi=fnd&pg=PR5&dq=ggplot2&ots=SAc\_My0SQR&sig=kxl4eEM08tk2hMmUo 469 5UgBJQE4AQ
- Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a
  major update to the DrugBank database for 2018. Nucleic Acids Res. 2018
  04;46(D1):D1074–82.
- 473 21. Gehlenborg N. UpSetR: A More Scalable Alternative to Venn and Euler Diagrams for
  474 Visualizing Intersecting Sets [Internet]. 2019. Available from: https://CRAN.R475 project.org/package=UpSetR
- 476 22. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via
   477 Coordinate Descent. Journal of Statistical Software. 2010;33(1):1–22.
- 478 23. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization Paths for Cox's Proportional
  479 Hazards Model via Coordinate Descent. Journal of Statistical Software. 2011;39(5):1–13.
- 480 24. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint 481 Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline 482 Corticosteroids for Palliative Versus Nonpalliative Indications. JCO. 2019 Jun 483 17;JCO.19.00189.
- 484
  485
  485
  486
  487
  486
  487
  486
  486
  487
  487
  487
  488
  488
  489
  489
  489
  480
  480
  480
  480
  480
  480
  481
  481
  481
  482
  483
  484
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485
  485

- Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, et al. Gut
  microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013 Nov
  1;62(11):1591–601.
- 489 27. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proceedings of the National Academy of Sciences. 2011 Mar 15;108(Supplement\_1):4554–61.
- 28. Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, et al. Antibiotics are associated with
  attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced nonsmall cell lung cancer. Lung Cancer. 2019 Apr;130:10–7.
- 495 29. Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics
  496 are associated with decreased progression-free survival of advanced melanoma patients
  497 treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(4):e1568812.
- 30. Chheda ZS, Sharma RK, Jala VR, Luster AD, Haribabu B. Chemoattractant Receptors
  BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8 <sup>+</sup> T Cell Migration into Tumors. JI. 2016 Sep 1;197(5):2016–26.
- Wu T, Yang L, Jiang J, Ni Y, Zhu J, Zheng X, et al. Chronic glucocorticoid treatment
   induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in
   rats. Life Sciences. 2018 Jan;192:173–82.
- 32. Garant A, Guilbault C, Ekmekjian T, Greenwald Z, Murgoi P, Vuong T. Concomitant use of
  corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid
  neoplasms: A systematic review. Critical Reviews in Oncology/Hematology. 2017
  Dec;120:86–92.
- Sola 33. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220–30.
- 510 34. González-Amaro R, Sánchez-Madrid F. Drugs, inflammation and cell adhesion receptors.
   511 Expert Opinion on Pharmacotherapy. 2001 Jan;2(1):3–17.
- 35. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact
  of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar;555(7698):623–8.
- 514 36. Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, et al. Modulation of peripheral
  515 blood immune cells by early use of steroids and its association with clinical outcomes in
  516 patients with metastatic non-small cell lung cancer treated with immune checkpoint
  517 inhibitors. ESMO Open. 2019 Feb;4(1):e000457.
- 518 37. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative
  519 association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with
  520 advanced renal cell and non-small-cell lung cancer. Annals of Oncology. 2018 Jun
  521 1;29(6):1437–44.
- 38. Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM. Non-steroidal antiinflammatory drugs, tumour immunity and immunotherapy. Pharmacological Research.
  2012 Jul;66(1):7–18.

- 525 39. Wang D, DuBois RN. Prostaglandins and cancer. Gut. 2006 Jan;55(1):115–22.
- 40. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016 May;65(5):749–56.
- 41. Boursi B, Mamtani R, Haynes K, Yang Y-X. Recurrent antibiotic exposure may promote
  cancer formation Another step in understanding the role of the human microbiota?
  European Journal of Cancer. 2015 Nov;51(17):2655–64.
- Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, et al. Rheumatic
  manifestations among cancer patients treated with immune checkpoint inhibitors.
  Autoimmunity Reviews. 2018 Mar;17(3):284–9.
- 43. Leonard J, Marshall JK, Moayyedi P. Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. Am J Gastroenterology. 2007 Sep;102(9):2047–56.
- 536 44. Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents
  537 on the outcome of patients with colorectal cancer. Cancer Treatment Reviews. 2014
  538 Feb;40(1):68–77.
- 45. Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, et al. Using Corticosteroids to
  Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases. Inflamm
  Bowel Dis. 2015 May;21(5):963–72.
- 542 46. Jala VR, Bodduluri SR, Satpathy SR, Chheda Z, Sharma RK, Haribabu B. The yin and
  543 yang of leukotriene B4 mediated inflammation in cancer. Semin Immunol. 2017;33:58–64.
- 544 47. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer
  545 Immunosurveillance. Cell. 2016 Apr 7;165(2):276–87.
- 546

# 548 FIGURES AND TABLES

- 549 Figure 1. Causal model for the effect of concomitant medications on Immunotherapy
- 550 **Response and Overall Survival.** Numbers along edges refer to references supporting the
- 551 connection. Hypothesized dominant pathways are shown in heavily-weighted edges. (1–3,8–
- 552 10,27–47)



553

Table 1. Cohort characteristics			
Overall n	690		
BMI (mean (SD))	27.79 (6.66)		
Staging (%)			
1	1 ( 0.2)		
2	4 ( 0.7)		
3	44 ( 7.2)		
4	548 (90.0)		
Unknown	12 ( 2.0)		
Age (mean (SD))	62.25 (13.21)		
Sex = Male (%)	403 (58.4)		
Cancer (%)			
Bladder Cancer	32 ( 4.9)		
Head and Neck Carcinoma	42 ( 6.5)		
Melanoma	185 (28.5)		
Non-Small Cell Lung Cancer	152 (23.4)		
Renal Cell Carcinoma	65 (10.0)		
Sarcoma	21 ( 3.2)		
Other	152 (23.4)		
Immunotherapy (%)			
Atezolizumab	22 ( 3.2)		
Durvalumab	12 ( 1.7)		
Durvalumab + Tremelimumab	6 ( 0.9)		
Ipilimumab	126 (18.3)		
Nivolumab	364 (52.8)		
Nivolumab + Ipilimumab	37 ( 5.4)		
Nivolumab + Chemotherapy	7(1.0)		
Pembrolizumab	104 (15.1)		
Tremelimumab	3 ( 0.4)		
Other	9 ( 1.3)		
ECOG (%)			
0	185 (31.0)		
1	272 (45.6)		
2	113 (19.0)		
> 2	26 ( 4.4)		
ABx within 28 days of ICI (mean (SD))	0.36 (0.48)		
CS within 28 days of ICI (mean (SD))	0.40 (0.49)		


Table 1. Cohort characteristics

## 556 Figure 2. The effect of medications at the start of ICI treatment across all cancers for A)

## 557 Antibiotics, B) Corticosteroids, and C) other medications. The cell color indicates the p-


value of the Kaplan-Meier curve and the "+" or "-" the direction of the HR, in reference to its

association with OS (i.e. a "-" indicates an association with decreased OS, therefore a HR > 1).




560

Figure 3. Associations of ABx and CS over time and by drug class. A) Hazard ratios with 95% confidence intervals of a Cox Proportional-Hazards model comparing individuals treated with ABx or CS during a 30-day sliding window compared to indivduals who did not receive ABx or CS, respectively. The significance and direction of associations of Cox Proportional Hazards models by (B) ABx or (C) CS class and cancer, using a window 28 days around ICI treatment start.





## 570 Figure 4. Combined models for ABx and CS and controlling for covariates. (A) Kaplan-


- 571 Meier curves for ABx and CS in combination. B) Cox Proportional Hazards model incorporating
- 572 both ABx and CS as well as several covariates. C) Cox-LASSO models for each cancer
- 573 showing the hazard ratios estimated for covariates and the number of times the covariate was
- 574 included in the model. The regularization parameter was selection by 10-fold cross validation,
- and then the robustness was assessed by 1000 bootstrap replicates using different random
- 576 samples of the data.



B) Combined model controlling for covariates








577

## 579 Figure 5. Relating the ABx effect to microbes enriched in responders to ICIs. A

- 580 dendrogram of the microbes recently shown to be most enriched in responders (black) or non-
- 581 responders (red), are related to known ABx susceptibilities (references for each cell in Table
- 582 **S1**). The ABx are ordered by hazard ratio across all cancers (i.e.  $\beta$ -lactams showed the largest
- 583 hazard ratio and linezolid the smallest).



584

## 586 SUPPLEMENTARY FIGURES AND TABLES

- 587 Figure S1. Causal diagram with references.
- 588 Figure S2. Number of medications prescribed across all cancers and the frequency of
- 589 multiple medications.
- 590 Figure S3. Number of antibiotics, separated by class, prescribed across all cancers and
- 591 the frequency of multiple antibiotics.
- 592 Figure S4. Number of corticosteroids, separated by class, prescribed across all cancers
- and the frequency of multiple antibiotics.
- 594 Table S1. References for the antibiotic susceptibilities of bacterial taxa found to be
- 595 enriched in responders or non-responders to ICI therapy